NEW YORK, March 4, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) will hold a conference call at 8:30 a.m. EST on Tuesday, March 8, 2005. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.
In order to participate in the conference call, please call 1-800-862-9098 (U.S.) or 1- 785-424-1051 (outside the U.S.). The call-in ID is "KERYX."
The press release announcing our financial results for the fourth quarter and year-end 2004 will be posted on the Company's website, www.keryx.com, prior to the call. The conference call will also be available for audio replay on our website for a period of 15 days after the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase II/III clinical program. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral AKT inhibitor in Phase II clinical development. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.